Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H12Cl2N2O |
| Molecular Weight | 271.142 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC1=NC2=C(O)C(Cl)=CC(Cl)=C2C=C1
InChI
InChIKey=YZPOQCQXOSEMAZ-UHFFFAOYSA-N
InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
| Molecular Formula | C12H12Cl2N2O |
| Molecular Weight | 271.142 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:32 UTC 2023
by
admin
on
Sat Dec 16 11:32:32 UTC 2023
|
| Record UNII |
Q7K6GJQ4O4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
747408-78-2
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
DTXSID701029571
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
10016012
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
DB05565
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
SUB196791
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
100000182617
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
PBT2
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease.Clinical trials: PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals, and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia. The drug also missed efficacy goals for Huntington's disease. | ||
|
Q7K6GJQ4O4
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->LIGAND |
Scientific Literature
|
||
|
TARGET->LIGAND |
Scientific Literature
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->LIGAND |
Scientific Literature
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antidementia, Dimethylamine, Hydroxyquinoline, Ionophore, Small molecule; Mechanism of Action: Chelating agent; Orphan Drug Status: Yes for Huntington's disease; Available For Licensing: Yes for Alzheimer's disease; Highest Development Phases: Phase II Alzheimer's disease, Huntington's disease; Most Recent Events: 30 Jun 2015 Adverse events data from the IMAGINE Extension trial in Alzheimer's disease released by Prana Biotechnology, 15 Jun 2015 Phase-II development is ongoing for the treatment of Alzheimer's disease and Huntington's disease, 01 Jun 2015 PBT 2 receives Orphan Drug status for Huntington's disease in European Union
|
||
|
ACTIVE MOIETY |
Drug Name: PBT-1033; Research Code: PBT-1033, PBT-2; MOA: Neural protective agent; Indication: Alzheimer's disease (AD), Huntington's disease; Status: Phase II (Active); Company: Prana (Originator)
|
